Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × Gemcitabine × Clear all

NCT06027268 2026-04-22

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03606967 2026-04-17

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07528768 2026-04-14

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

Recurrence, Triple Negative Breast Neoplasms

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Unknown

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04297267 2022-07-22

nonpCR GP

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT02341911 2022-04-20

TNBC

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT02978716 2022-03-23

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Phase 2 Terminated

102 enrolled 51 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04517292 2020-08-18

GEP

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00813956 2016-03-17

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT00540358 2012-12-28

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00601159 2011-07-04

Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms